JHS Svendgaard Laboratories Limited

As of June 30, 2026, JHS Svendgaard Laboratories Limited carries a market capitalization of 646.31M, placing it among publicly traded companies globally. Its enterprise value stands at 646.31M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, JHS Svendgaard Laboratories Limited has 85.60M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, JHS Svendgaard Laboratories Limited trades at an EV/EBITDA multiple of 21.36 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.60 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 646.31M versus a market cap of 646.31M, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 4.36M in revenue per employee across its workforce of 249.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, JHS Svendgaard Laboratories Limited recorded an income tax benefit of -9.69M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -28.56M and -18.87M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, JHS Svendgaard Laboratories Limited's stock has declined approximately 32.60% over the past 52 weeks. The 50-day moving average sits at 8.88, while the 200-day moving average is 8.83.

Over the twelve months ended June 30, 2026, JHS Svendgaard Laboratories Limited generated 1.09B in revenue and converted that into -18.87M in net income, yielding earnings per share of -0.21. EBITDA reached 30.26M, while operating income came in at -44.11M.

Over the twelve months ended June 30, 2026, JHS Svendgaard Laboratories Limited posted a gross margin of 34.17, reflecting its pricing power and cost economics. The operating margin of -4.06 and net profit margin of -1.74 provide insight into operational efficiency.